Tianzhou Yu

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 7

Top Topics

Drug Administration

Diffuse Large B Cell Lymphoma

Acute Lymphoblastic Leukemia

Top Venues

Health and quality of life outcomes

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Jee H Choe, Tianzhou Yu, Jeremy S Abramson, Mohamed Abou-El-Enein
Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma. Blood advances 8 (2) (2024)
Jee H Choe, Tianzhou Yu, Jeremy S Abramson, Mohamed Abou-El-Enein
Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma. Blood advances 8 (2) (2024)
Jee H Choe, Tianzhou Yu, Jeremy S Abramson, Mohamed Abou-El-Enein
Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma. Blood advances 8 (2) (2024)
Jee H Choe, Tianzhou Yu, Jeremy S Abramson, Mohamed Abou-El-Enein
Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma. Blood advances 8 (2) (2024)
Tianzhou Yu, Shihan Jin, Chang Li, James D Chambers, Jakub P Hlávka
Factors Associated with Biosimilar Exclusions and Step Therapy Restrictions Among US Commercial Health Plans. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2023)
Jee H Choe, Tianzhou Yu, Jeremy S Abramson, Mohamed Abou-El-Enein
Cost-Effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma. Blood advances (2023)
Tianzhou Yu, Jiafan Chen, Ning Yan Gu, Joel W Hay, Cynthia L Gong
Predicting panel attrition in longitudinal HRQoL surveys during the COVID-19 pandemic in the US. Health and quality of life outcomes 20 (1) (2022)